Mucoactive and antioxidant medicines for COPD: consensus of a group of Chinese pulmonary physicians

References

• ZhongNWangCYaoWPrevalence of chronic obstructive pulmonary disease in China: a large, population-based surveyAm J Respir Crit Care Med2007176875376017575095
   PubMed Web of Science ®Google Scholar
• GBD 2013 Mortality and Causes of Death CollaboratorsGlobal, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013Lancet2015385996311717125530442
   PubMed Web of Science ®Google Scholar
• Soler-CataluñaJJMartínez-GarcíaMARomán SánchezPSalcedoENavarroMOchandoRSevere acute exacerbations and mortality in patients with chronic obstructive pulmonary diseaseThorax2005601192593116055622
   PubMed Web of Science ®Google Scholar
• DonaldsonGCSeemungalTABhowmikAWedzichaJARelationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary diseaseThorax2002571084785212324669
   PubMed Web of Science ®Google Scholar
• ZhengJPKangJHuangSGEffect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled studyLancet200837196292013201818555912
   PubMed Web of Science ®Google Scholar
• ZhengJPWenFQBaiCXTwice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trialLancet Respir Med20142318719424621680
   PubMed Web of Science ®Google Scholar
• LuWZhengJThe function of mucins in the COPD airwayCurr Respir Care Rep201323155166
   Google Scholar
• De MarcoRAccordiniSCerveriIIncidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegmAm J Respir Crit Care Med20071751323917008642
   PubMed Web of Science ®Google Scholar
• KhuranaSRaviASutulaJClinical characteristics and airway inflammation profile of COPD persistent sputum producersRespir Med2014108121761177025459449
   PubMed Web of Science ®Google Scholar
• VestboJPrescottELangePAssociation of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study GroupAm J Respir Crit Care Med19961535153015358630597
   PubMed Web of Science ®Google Scholar
• VestboJEpidemiological studies in mucus hypersecretionNovartis Found Symp2002248312 Discussion 12–19, 277–28212568485
   PubMed Web of Science ®Google Scholar
• BurgelPRNesme-MeyerPChanezPCough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjectsChest2009135497598219017866
   PubMed Web of Science ®Google Scholar
• FischerBMVoynowJAGhioAJCOPD: balancing oxidants and antioxidantsInt J Chron Obstruct Pulmon Dis20151026127625673984
   PubMed Web of Science ®Google Scholar
• SantusPCorsicoASolidoroPBraidoFDi MarcoFScichiloneNOxidative stress and respiratory system: pharmacological and clinical reappraisal of N-acetylcysteineCOPD201411670571724787454
   PubMedGoogle Scholar
• KinnulaVLIlumetsHMyllarniemiMSovijärviARytiläP8-Isoprostane as a marker of oxidative stress in non symptomatic cigarette smokers and COPDEur Respir J2007291515517050565
   PubMed Web of Science ®Google Scholar
• MontuschiPCollinsJVCiabattoniGExhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokersAm J Respir Crit Care Med20001623Pt 11175117710988150
   PubMed Web of Science ®Google Scholar
• MakrisDParaskakisEKorakasPExhaled breathcondensate 8-isoprostane‚ clinical parameters‚ radiological indices and airway inflammation in COPDRespiration200875213814417641539
   PubMed Web of Science ®Google Scholar
• García-RioFRomeroDLoresVDynamic hyperinflation, arterial blood oxygen, and airway oxidative stress in stable patients with COPDChest2011140496196921436248
   PubMed Web of Science ®Google Scholar
• DavisSSScobieSInglisAThe effect of sulphydryl compounds and cross linking agents on the viscous and viscoelastic properties of mucusBiorheology1975123–42252321125
   PubMed Web of Science ®Google Scholar
• SamuniYGoldsteinSDeanOMBerkMThe chemistry and biological activities of N-acetylcysteineBiochim Biophys Acta2013183084117412923618697
   PubMed Web of Science ®Google Scholar
• MataMRuizACerdaMOral N-acetylcysteine reduces bleomycin-induced lung damage and mucin Muc5ac expression in ratsEur Respir J200322690090514680076
   PubMed Web of Science ®Google Scholar
• RogersDFMucoactive agents for airway mucus hypersecretory diseasesRespir Care200752911761193 Discussion 1193–119717716385
   PubMed Web of Science ®Google Scholar
• SadowskaAMVan OverveldFJGóreckaDThe interrelationship between markers of inflammation and oxidative stress in chronic obstructive pulmonary disease: modulation by inhaled steroids and antioxidantRespir Med200599224124915715193
   PubMed Web of Science ®Google Scholar
• KasielskiMNowakDLong-term administration of N-acetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary diseaseRespir Med200195644845611421501
   PubMed Web of Science ®Google Scholar
• SzkudlarekUZdziechowskiAWithkowskiKEffect of inhaled N-acetylcysteine on hydrogen peroxide exhalation in healthy subiectsPulm Pharmacol Ther200417315516215123225
   PubMed Web of Science ®Google Scholar
• EklundAErikssonOHakanssonLOral N-acetylcysteine reduces selected humoral markers of inflammatory cell activity in BAL fluid from healthy smokers: correlation to effects on cellular variablesEur Respir J1988198328382852604
   PubMed Web of Science ®Google Scholar
• Van OverveldFJVermeirePADe BackerWAInduced sputum of patients with chronic obstructive pulmonary disease (COPD) contains adhesion-promoting, therapy-sensitive factorsInflamm Res200049181310778915
   PubMed Web of Science ®Google Scholar
• RiiseGCQvarfordtILarssonSInhibitory effect of N-acetycysteine on adherence of Streptococcus pneumoniae and Haemophilus influenzae to human orophryngeal epithelial cells in vitroRespiration200067555255811070462
   PubMed Web of Science ®Google Scholar
• MataMMorcilloEGimenoCN-acetyl-L-cysteine (NAC) inhibits mucin synthesis and pro-inflammatory mediators in alveolar type II epithelial cells infected with influenza virus A and B and with respiratory syncytial virus (RSV)Biochem Pharmacol201182554855521635874
   PubMed Web of Science ®Google Scholar
• MataMSarrionIArmengotMRespiratory syncytial virus inhibits ciliagenesis in differentiated normal human bronchial epithelial cells: effectiveness of N-acetylcysteinePLoS One2012710e4803723118923
   PubMed Web of Science ®Google Scholar
• YaoHRahmanICurrent concepts on oxidative/carbonyl stress, inflammation and, epigenetics in pathogenesis of chronic obstructive pulmonary diseaseToxicol Appl Pharmacol20112542728521296096
   PubMed Web of Science ®Google Scholar
• BragaPCAllegraLRampoldiCLong-lasting effects on rheology and clearance of bronchial mucus after short-term administration of high doses of carbocysteinelysine to patients with chronic bronchitisRespiration19905763533582099568
   PubMed Web of Science ®Google Scholar
• MacciòAMadedduCPanzoneFMantovaniGCarbocysteine: clinical experience and new perspectives in the treatment of chronic inflammatory diseasesExpert Opin Pharmacother200910469370319239402
   PubMed Web of Science ®Google Scholar
• CarpagnanoGERestaOFoschino-BarbaroMPExhaled interleukine-6 and 8-isoprostane in chronic obstructive pulmonary disease: effect of carbocysteine lysine salt monohydrate (SCMC-Lys)Eur J Pharmacol20045051–316917515556150
   PubMed Web of Science ®Google Scholar
• IshibashiYOkamuraTMasumotoYTachiiriTMomoKEffects of carbocisteine on airway inflammation and related events in SO2-exposed ratsNihon Kokyuki Gakkai Zasshi20013911723 Article in Japanese11296380
   PubMedGoogle Scholar
• CakanGTurkozMTuranTAhmedKNagatakeTS-carboxymethylcysteine inhibits the attachment of Streptococcus pneumoniae to human pharyngeal epithelial cellsMicrob Pathog200334626126512782478
   PubMed Web of Science ®Google Scholar
• MiyakeKKaiseTHosoeHAkutaKManabeHOhmoriKThe effect of erdosteine and its active metabolite on reactive oxygen species production by inflammatory cellsInflamm Res199948420520910344471
   PubMed Web of Science ®Google Scholar
• MorettiMPharmacology and clinical efficacy of erdosteine in chronic obstructive pulmonary diseaseExpert Rev Respir Med20071330731620477170
   PubMedGoogle Scholar
• Dal NegroRWErdosteine: antitussive and anti-inflammatory effectsLung2008186suppl 1S70S7318185958
   PubMed Web of Science ®Google Scholar
• FarkhutdinovURFarkhutdinovRRPetriakovWEffect of mucolytic therapy on the production of reactive oxygen species in the blood of patients with an exacerbation of chronic obstructive pulmonary diseaseTer Arkh20108232932
   Web of Science ®Google Scholar
• YakootMSalemAOmarAMClinical efficacy of farcosolvin syrup (ambroxol-theophylline-guaiphenesin mixture) in the treatment of acute exacerbation of chronic bronchitisInt J Chron Obstruct Pulmon Dis201095251256
   Google Scholar
• RogemDFMucus hypersecretion in chronic obstructive pulmonary diseaseNovaflis Nund Syrup20012346572
   Google Scholar
• RubinBKSecretion properties, clearance, and therapy in airway diseaseTransl Respir Med201426 eCollection 201425505698
   PubMedGoogle Scholar
• PelaRCalcagniAMSubiacoSIsidoriPTubaldiASanguinettiCMN-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPDRespiration199966649550010575333
   PubMed Web of Science ®Google Scholar
• DecramerMRutten-van MolkenMDekhuijzenPNEffects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trialLancet200536594701552156015866309
   PubMed Web of Science ®Google Scholar
• TseHNRaiteriLWongKYHigh-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE studyChest2013144110611823348146
   PubMed Web of Science ®Google Scholar
• PoolePBlackPNCatesCJMucolytic agents for chronic bronchitis or chronic obstructive pulmonary diseaseCochrane Database Syst Rev20128CD001287
   Google Scholar
• AllegraLCordaroCIGrassiCPrevention of acute exacerbations of chronic obstructive bronchitis with carbocysteine lysine salt monohydrate: a multicenter, double-blind, placebo controlled trailRespiration19966331741808739489
   PubMed Web of Science ®Google Scholar
• MorettiMBottrighiPDallariRThe effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE StudyDrugs Exp Clin Res200430414315215553660
   PubMedGoogle Scholar
• MalerbaMPonticielloARadaeliAEffect of twelve-months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multicenter, placebo-controlled study (the AMETHIST Trial)Pulm Pharmacol Ther2004171273414643168
   PubMed Web of Science ®Google Scholar
• MarchioniCFPoluJMTaytardAEvaluation of efficacy and safety of erdosteine in patients affected by chronic bronchitis during an infective exacerbation phase and receiving amoxycillin as basic treatment (ECOBES, European Chronic Obstructive Bronchitis Erdosteine Study)Int J Clin Pharmacol Ther199533116126188688986
   PubMed Web of Science ®Google Scholar
• AubierMBerdahLMulticenter, controlled, double – blind study of the efficacy and tolerance of Vectrine (erdostein) versus placebo in the treatment of stabilized chronic bronchitis with hypersecretionRev Mal Respir199916452152810549062
   PubMed Web of Science ®Google Scholar
• GerritsCMHeringsRMLeufkensHGLammersJWN-acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary diseaseEur Respir J200321579579812765423
   PubMed Web of Science ®Google Scholar
• VestboJHurdSSAgustiAGGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summaryAm J Respir Crit Care Med2013187434736522878278
   PubMed Web of Science ®Google Scholar
• StavDRazMEffect of N-acetylcysteine on air trapping in COPD: a randomized placebo-controlled studyChest2009136238138619447919
   PubMed Web of Science ®Google Scholar
• LangenRCKornSHWoutersEFROS in the local and systemic pathogenesis of COPDFree Radic Biol Med200335322623512885585
   PubMed Web of Science ®Google Scholar
• VestboJPrescottEAlmdalTBody mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart StudyAm J Respir Crit Care Med20061731798316368793
   PubMed Web of Science ®Google Scholar
• MatuszczakYFaridMJonesJEffects of N-acetylcysteine on glutathione oxidation and fatigue during handgrip exerciseMuscle Nerve200532563363816025522
   PubMed Web of Science ®Google Scholar
• CornSDBarstowTJEffects of oral N-acetylcysteine on fatigue, critical power, and W’ in exercising humansRespir Physiol Neurobiol2011178226126821740986
   PubMed Web of Science ®Google Scholar
• ZuinRPalamideseANegrinRHigh dose N-Acetylcysteine in patients with exacerbations of chronic obstructive pulmonary diseasesClin Drug Invest2005256401408
   PubMed Web of Science ®Google Scholar
• WangJBaoHChenXEffects of ambroxolon serum cytokine and pulmonary function in AECOPD patientsClin Pulm J2010152194195
   Google Scholar
• BehrJDemedtsMBuhlRLung function in idiopathic pulmonary fibrosis-extended analyses of the IFIGENIA trialRespir Res20091010119860915
   PubMed Web of Science ®Google Scholar
• VestboJHurdSSAgustíAGGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2013187434736522878278
   PubMed Web of Science ®Google Scholar
• YanXSongYShenCChinese experts consensus on AECOPD (revision)Int J Respir2014341111
   Google Scholar
• CrinerGJBourbeauJDiekemperRLPrevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society GuidelineChest2015147489494225321320
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung DiseaseGlobal Strategy for Diagnosis, Management, and Prevention of COPD – 2016 Available from: http://goldcopd.org/global-strategy-diagnosis-management-prevention-copd-2016/Accessed June 1, 2016
   Google Scholar